Pharma IQ Members

White Papers

Pharma is devoted to providing pharma professionals with the most comprehensive selection of case studies and white papers on the internet. Get in-depth information through Pharma IQ's pharma and biotechnology white papers. Our white papers aim to educate industry leaders as they make complex business decisions that drive growth, innovation and ROI. 

328 whitepaper results
of -1

At UPS, our core business involves helping companies manage change, so we’ve been in the trenches through a wide range of mergers, acquisitions and divestitures – in healthcare and non-healthcare sectors alike. And as a global company ourselves, UPS acquired six companies in Europe in the last 3 years. So we appreciate the perils and pitfalls of the journey. For companies in the healthcare sector, that process can be particularly fraught – given the nature of the products, the complexity of the supply chains and the stringent regulations involved. Fortunately, there are practical, tactical strategies that can decisively impact the final outcome. In our experience, a major restructuring is an opportunity to create transformational change that significantly enhances long-term competitiveness and performance. In this white paper, we outline some very pragmatic, actionable strategies we’ve gleaned in our experience working in this sector.Taking The Supply Chain Pain Out Of Healthcare Mergers And Acquisitions

Tags:

Pharma IQ examined the market to pinpoint the forecasted trends for the market next year. After consulting the expertise of an array of industry specialists, Pharma & Cold Chain IQ presents itstop predicted trends for 2016.In regards to the approaching year, Dr Steven Bradshaw European Director of Market Access Solutions noted: “2016 should be an interesting year in pharma. Some of the main items to watch are the effect of key biosimilar entries and the... Learn more

Tags:

In the combat against counterfeit drugs, more than 40 markets – those of which including the EU, US, South Korea, Brazil and China, are deploying pharmaceutical track and trace laws. According to industry specialist Tracelink, by the end of 2018 more than 75% of the globe’s prescription medications are expected to be protected by legislation.  As the pharma industry advances towards a state of airtight track and trace compliance, Pharma IQ’s Global Pharmaceutical Serialisation and... Learn more

Tags:

Pharma IQ presents the top content pieces for 2015 in this annual bumper, so you can browse through some of this year’s best articles to feature on the portal.Top Content For 2015

Tags:

Earlier this month Pharma IQ opened up the opportunity for pharma and biotech professionals to submit their burning compliance questions on software for medical devices. Now, the MHRA’s Senior Regulatory Specialist for Devices –Rob Higgins - takes the floor on the subject.MHRA Sounds Wake-Up Call for Medical Software Manufacturers

As the biopharmaceutical industry's focus moves from a blockbuster sales model to more targeted therapeutics, the need to avoid costly investments in sizable stainless steel equipment is increasing. The use of single-use bioprocessing equipment is making product manufacture increasingly efficient and frequently less costly, particularly for early stages such as R&D and clinical trials. This is particularly important for smaller and lesser-funded companies, for whom using single-use equipment for in-house candidate product manufacture is one of the only viable options (aside from outsourcing).Investment Trends In Single Use Systems

A dominating focus of today’s single use systems in biomanufacturing is the road towards standardisation between equipment suppliers. The absence of standardisation between single use system suppliers is seen as a key discourager to end users despite the many advantages the format provides to the pharma and biotech production process. Advantages to single use system standardisation include the avoidance of costs for system modification and faster implementation. (2)Standardisation within Single Use Systems An Inevitability, But Does It Have To Be Painful?

Innovation is thought to be a keystone in the process of being competitive in anymarket. Within clinical trial supply, a lack of innovation can be costly in regards to a range of variables. With this in mind, Pharma IQ discusses the latest trailblazing techniques in the arena with a panel of Clinical Trial Supply specialists.Innovation in Clinical Trial Supply

This paper explores how a single, enterprise data-management platform can improve biologics development lifecycles. The paper examines the challenges faced by biopharmaceutical professionals in their drive to develop novel biologics and more effective bioprocesses, and how they can be overcome.Data Challenges in Biologics Development

There are a number of limitations to CRISPR Cas9, which curb its ascent within today’s market. In response to this, Pharma IQ has conducted some primary research exploring the challenges encountered with the CRISPR Cas9 method and the key solutions.CRISPR Cas9 Troubleshooting Analysis

Tags: CRISPRCAS9 | CRISPR
328 whitepaper results
of -1